Kindred Biosciences, a biopharmaceutical company focusing on pet medications, will release its Q3 2020 financial results on November 9, 2020, after market close. A conference call will be held at 4:30 p.m. ET, which can be accessed via phone or a live webcast. The company aims to develop safe and effective treatments for pets, leveraging successful human-target therapeutics.
Kindred Biosciences (NASDAQ: KIN) announced positive results from a pivotal efficacy study of KIND-030, a monoclonal antibody targeting canine parvovirus (CPV). The study demonstrated 100% efficacy in preventing CPV, with treated dogs showing no mortality compared to 60% in the control group. KIND-030 is being developed both as prophylactic therapy and for treating established CPV infections. The company anticipates completing pivotal safety studies by year-end 2020, with regulatory approval expected in early 2021. This product addresses a significant unmet need given the high mortality rates associated with CPV.
Kindred Biosciences (NASDAQ: KIN), a biopharmaceutical firm focused on pet health, will participate in three upcoming conferences. These include the H.C. Wainwright Global Investment Conference on September 14-15, the Cantor Global Healthcare Conference on September 16, and the Lake Street Best Ideas Growth Conference on September 17, 2020. CEO Richard Chin will present and hold one-on-one meetings to discuss recent developments, study results, and future milestones. Investors can access webcasts of the presentations through the company's website.
Kindred Biosciences, Inc. (NASDAQ: KIN) reported strong financial results for Q2 2020, with net revenues of $39.6 million and net income of $24.0 million, equating to $0.60 per share. The company highlighted progress on its biologics pipeline, including the initiation of pivotal studies for its canine parvovirus and IL-31 antibody candidates. The sale of Mirataz to Dechra Pharmaceuticals generated significant revenue, although equine product sales were impacted by COVID-19. KindredBio maintains a positive outlook, anticipating operating expenses between $53-$55 million for the year.
Kindred Biosciences, Inc. (NASDAQ: KIN) will announce its second quarter 2020 financial results on August 5, 2020, after market close, followed by a conference call at 4:30 p.m. Eastern time. Investors can access the call toll-free at (888) 771-4371 or internationally at (847) 585-4405 using conference ID 49852246. The call will also be webcast live, with a replay available for 30 days. Kindred aims to develop innovative biologics for pets, paralleling safe and effective human medicines.